---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-117515"
form_type: "8-K"
ticker: "HIND"
cik: "0001427570"
company_name: "Vyome Holdings, Inc"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:49:17.420708+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ReShape Lifesciences announces $750k offering with Series D preferred and warrant repricing

## Summary
- Gross proceeds $750k from sale of 2.39M shares, 2,500 Series D preferred, and pre-funded warrants at $0.26/share.
- Common warrants to purchase 2.88M shares at $0.30, exercisable after 6 months, expire 5.5 years.
- Existing warrants for 5.35M shares amended: exercise price cut to $0.30, non-exercisable for 6 months, extended expiry.
- Company to seek shareholder approval for reverse split and increase authorized shares from 100M to 300M.

## SEC filing metadata
- accession: 0001104659-22-117515
- form_type: 8-K
- ticker: HIND
- cik: 0001427570
- company_name: Vyome Holdings, Inc
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427570/000110465922117515/0001104659-22-117515-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427570/000110465922117515/tm2230281d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-117515
- JSON: https://secwatch.observer/filing/0001104659-22-117515.json
- Plain text: https://secwatch.observer/filing/0001104659-22-117515.txt

## Key facts
- Material Agreements
  Vyome Holdings, Inc entered into Securities Purchase Agreement valued at $750,000 (effective 2022-11-08).
  - Action: entry
  - Agreement: equity purchase
  - Value: $750,000
  - Effective: 2022-11-08
  source text: On November 8, 2022, ReShape Lifesciences Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a certain institutional investor (the “Investor”), pursuant to which the Company agreed to issue and sell to the Investor in a registered direct offering (the “Registered Offering”) (i) 2,392,524 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) 2,500 shares of the Company’s Series D Mirroring Preferred Stock, par value $0.001 per share and stated value of $0.001 per share (the “Preferred Stock”), and (iii) pre-funded warrants to purchase an aggregate of 492,091 shares of Common Stock (the “Pre-funded Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000110465922117515/0001104659-22-117515-index.htm
- Material Agreements
  Vyome Holdings, Inc amended Warrant Amendment Agreement.
  - Action: amendment
  source text: In connection with the Offering, the Company also entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with the Investor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1427570/000110465922117515/0001104659-22-117515-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.